Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas

Archives of Pathology and Laboratory Medicine

Volumn 125, Issue 10, 2001, Pages 1316-1320

  Foster, M R ^a   Johnson, J E ^a   Olson, S J ^a   Allred, D C ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CALRETININ; MUCIN; PROTEIN WT1; THROMBOMODULIN; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; ELECTRON MICROSCOPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MALIGNANT MESOTHELIOMA; RELIABILITY; SENSITIVITY AND SPECIFICITY; STAINING;

ADENOCARCINOMA; CELL NUCLEUS; CYTOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MESOTHELIOMA; STAINING AND LABELING; WT1 PROTEINS;

EID: 0034775429     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Moc-31 aids in the differential between adenocarcinoma and reactive mesothelial cells
2. Value of calretinin immunostaining in differentiating epithelial mesothelionna from lung adenocarcinoma
3. Value of Ber-EP4 antibody in differentiating epithelial pleural mesothelionna from adenocarcinoma
4. Value of thrombomodulin immunostaining in the diagnosis of mesothelioma
5. Calretinin: A novel immunocytochemical marker for mesothelioma
6. Utility of the antibodies CA 19-9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology
7. A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumors
8. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type
9. Mesothelioma-binding antibodies: Thrombomodulin, OV-632, and HBME-1 and their use in the diagnosis of malignant mesothelioma
10. HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of the pleura
11. CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma
12. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma
13. Value of thyroid transcription factor-1, E-cadherin, BG8, WT-1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma
14. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma
15. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma
16. The role of immunohistochemistry in the diagnosis of malignant mesothelioma
17. The candidate Wilms tumor gene is involved in genitourinary development
18. Tissue, developmental and tumor-specific expression of divergent transcripts in Wilms tumor
19. The Wilms tumor gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma
20. Comparative in situ hybridization analysis of PAX2, PAX8, and WT1 gene transcription in human fetal kidney and Wilms' tumors
21. Wilms' tumor suppressor gene expression in rat and human mesothelioma
22. Expression of the Wilms' tumor gene WT1 in human malignant mesothelioma cell lines and relationship to platelet-derived growth factor A and insulin-like growth factor 2 expression
23. Immunohistochemical demonstration of Wilms tumor gene product WT1 in a canine neuroepithelioma: Providing evidence for its classification as an extrarenal nephroblastoma
24. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth
25. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression cell-type transition, and prognosis
26. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing
27. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma
28. HBME, MOC-31 and calretinin: An assessment of recently described markers for mesothelioma and adenocarcinoma
29. In search of a positive immunohistochemical marker for mesothelioma: An update
30. The immunohistochemical diagnosis of epithelial mesothelioma
31. Calretinin: A selective marker of normal and neoplastic mesothelial cells in serous effusions
32. E-cadherin and calretinin: A useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma
33. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura
34. The immunohisto-chemical diagnostic panel for epithelial mesothelioma: A reevaluation after heat-induced epitope retrieval
35. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma